Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lisdexamfetamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lisdexamfetamine SCHEMBL970534 | 1.00 | MMP2 (0.59) | MMP2THRBNPC1RAB9ALTA4H | |
| Lisdexamfetamine SCHEMBL29124173 | 1.00 | MMP2 (0.59) | MMP2THRBNPC1RAB9ALTA4H | |
| Lisdexamfetamine SCHEMBL158949 | 0.95 | MMP2 (0.64) | MMP2THRBNPC1RAB9ALTA4H | |
| Lisdexamfetamine SCHEMBL31439237 | 0.95 | MMP2 (0.64) | MMP2THRBNPC1RAB9ALTA4H | |
| Lisdexamfetamine SCHEMBL25674417 | 0.95 | MMP2 (0.64) | MMP2THRBNPC1RAB9ALTA4H | |
| Lisdexamfetamine SCHEMBL12947679 | 0.95 | MMP2 (0.64) | MMP2THRBNPC1RAB9ALTA4H | |
| Lisdexamfetamine SCHEMBL579061 | 0.95 | MMP2 (0.64) | MMP2THRBNPC1RAB9ALTA4H | |
| Lisdexamfetamine SCHEMBL7919487 | 0.95 | MMP2 (0.64) | MMP2THRBNPC1RAB9ALTA4H | |
| Lisdexamfetamine SCHEMBL31173641 | 0.95 | MMP2 (0.64) | MMP2THRBNPC1RAB9ALTA4H | |
| SCHEMBL972499 | 0.94 | MMP2 (0.60) | MMP2THRBNPC1RAB9ALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034151-A1 | TREATMENT OF FRAGILE X SYNDROME AND AUTISM SPECTRUM DISORDER WITH CANNABIDIOL | HARMONY BIOSCIENCES MANAGEMENT, INC. (US) | 2026-02-05 | — | — | US | claimed |
| US-20250288539-A1 | TREATMENT OF FRAGILE X SYNDROME AND AUTISM SPECTRUM DISORDER WITH CANNABIDIOL | HARMONY BIOSCIENCES MANAGEMENT, INC. (US) | 2025-09-18 | — | — | US | claimed |
| WO-2024249914-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DYSTONIA | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | WO | claimed |
| EP-4157236-A1 | TREATMENT OF AUTISM SPECTRUM DISORDER WITH CANNABIDIOL | Zynerba Pharmaceuticals, Inc. (US) | 2023-04-05 | — | — | EP | claimed |
| CN-109912683-B | Cytotoxin molecule, conjugate, preparation method and application thereof | 杭州多禧生物科技有限公司 | 2023-01-06 | — | — | CN | claimed |
| CN-115505029-A | Cytotoxin molecule, conjugate, preparation method and application thereof | 杭州多禧生物科技有限公司 | 2022-12-23 | — | — | CN | claimed |
| US-12611418-B2 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | COMPASS PATHFINDER LIMITED (GB) | 2026-04-28 | — | — | US | disclosed |
| US-12582620-B2 | Oral solutions comprising lisdexamfetamine salts | ADALVO LIMITED (MT) | 2026-03-24 | — | — | US | disclosed |
| US-12582664-B2 | Treatment of fragile x syndrome with cannabidiol | HARMONY BIOSCIENCES MANAGEMENT, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260034151-A1 | TREATMENT OF FRAGILE X SYNDROME AND AUTISM SPECTRUM DISORDER WITH CANNABIDIOL | HARMONY BIOSCIENCES MANAGEMENT, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250367223-A1 | METHODS FOR TREATING ANXIETY DISORDERS, HEADACHE DISORDERS, AND EATING DISORDERS WITH PSILOCYBIN | COMPASS PATHFINDER LIMITED (GB) | 2025-12-04 | — | — | US | disclosed |
| EP-4215517-B1 | COMPOUND AND METHOD FOR PREPARATION OF LISDEXAMFETAMINE | SCI PHARMTECH INC (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-17 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112017-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | GABRB2, GAP43, GABRB1 | MMP2 3003/4885THRB 352/4885NPC1 1375/4885 |
| US-20260034151-A1 | TREATMENT OF FRAGILE X SYNDROME AND AUTISM SPECTRUM DISORDER WITH CANNABIDIOL | CTNND1, SOX18, FZD7 | MMP2 3418/4885THRB 869/4885NPC1 3337/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | MMP2 506/4885THRB 765/4885NPC1 1898/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | MMP2 1830/4885THRB 3558/4885NPC1 2433/4885 |
| US-12582620-B2 | Oral solutions comprising lisdexamfetamine salts | MTTP, TPMT, DUSP10 | MMP2 2266/4885THRB 1378/4885NPC1 1860/4885 |
| US-12611418-B2 | Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin | HTR1D, HTR1B, HTR2B | MMP2 4264/4885THRB 382/4885NPC1 239/4885 |
| US-12582664-B2 | Treatment of fragile x syndrome with cannabidiol | CTNND1, CYFIP1, CYFIP2 | MMP2 4139/4885THRB 1715/4885NPC1 504/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | MMP2 798/4885THRB 334/4885NPC1 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.